FIELD: medicine, pharmaceutics.
SUBSTANCE: presented group of inventions refers to medicine. There are presented method, use and pharmaceutical composition for prevention and treatment of carbohydrate and lipid metabolism disorders in metabolic syndrome and encephalopathy of atherosclerotic, vascular genesis and diabetic encephalopathy, including the introduction of tetrapeptide Pro-Gly-Pro-Leu of general formula.
EFFECT: higher effectiveness of prevention and treatment of carbohydrate and lipid metabolism disorders in metabolic syndrome and encephalopathy due to the use of the tetrapeptide Pro-Gly-Pro-Leu.
5 cl, 1 dwg, 6 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USING TETRAPEPTIDE Pro-Gly-Pro-Val AS AGENT FOR PREVENTING AND TREATING LIPID STORAGE DISEASE, METHOD FOR PREVENTING AND TREATING LIPID STORAGE DISEASE, PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING LIPID STORAGE DISEASE AND METHOD FOR PREPARING IT | 2013 |
|
RU2537133C2 |
| USING TETRAPEPTIDE Arg-Pro-Gly-Pro AS AGENT FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, METHOD FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA, PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING HYPERCHOLESTEREMIA AND METHOD FOR PREPARING IT | 2013 |
|
RU2538801C2 |
| APPLICATION OF Pro-Gly-Pro-Leu TETRAPEPTIDE AS AGENT FOR PREVENTION AND TREATMENT OF DIABETES, METHOD FOR PREVENTION AND TREATMENT OF DIABETES AND PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES | 2008 |
|
RU2378005C1 |
| METHOD OF TREATING AND/OR PREVENTION OF EXCESSIVE BODY WEIGHT AND/OR OBESITY AND/OR METABOLIC DISORDERS | 2008 |
|
RU2403038C2 |
| FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE | 2020 |
|
RU2804335C2 |
| APPLICATION OF Thr-Lys-Pro-Arg-Pro-Gly-Pro PEPTIDE (SELANK) FOR TOXIC HEPATITIS PREVENTION AND TREATMENT | 2017 |
|
RU2640133C1 |
| PHARMACEUTICAL COMPOSITION, MEDICATION FOR PREVENTION AND TREATMENT OF METABOLIC SYNDROME AND DIABETIC NEPHROPATHY AND METHOD OF OBTAINING THEREOF | 2011 |
|
RU2519744C2 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF OBESITY AND ASSOCIATED METABOLIC DISORDERS | 2020 |
|
RU2763348C2 |
| COMPOSITION FOR METABOLIC SYNDROME CORRECTION | 2016 |
|
RU2616241C1 |
| USING LACTITOL AND AN ORAL DOSAGE FORM FOR TREATING AND PREVENTING NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2692243C1 |
